Zenas BioPharma, Inc. Common Stock (ZBIO) Stock Price
ZBIOStock
$33.77+85.09%52W
Market Cap$2.20B
P/E—
PEG Ratio—
Div yield—
Beta0.70
ZBIO Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)7.38%
Price vs S&P 500 (4W)-5.03%
VGM Score83.99
ZBIO Earnings Surprise History
Q2 25-1.25est. -1.06
Q3 25-1.22est. -0.85
Q4 25-1.39est. -1.19
Q1 26-1.46est. -1.54
Q2 26-1.77est. -0.76
ZBIO Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.36
4.36
4.36
4.36
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ZBIOZenas BioPharma, Inc. Common Stock | — | A | A | $33.77 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma is a clinical-stage biopharmaceutical company focused on treating autoimmune diseases with obexelimab, a monoclonal antibody. The drug candidate targets B cells by binding to CD19 and FcyRIIb receptors, inhibiting their disease-driving activity while preserving cell survival—a mechanism designed to provide a differentiated treatment approach. This unique profile addresses a significant gap in autoimmune disease therapy.